COVID-19 vaccine: the challenges of running a trial in the middle of a pandemic

JBy: Jeffrey Mphahlele, South African Medical Research Council

A volunteer receives an injection from a medical worker during the country’s first human clinical trial for a potential vaccine against COVID-19 in Soweto, South Africa.
Felix Dlangamandla/Beeld/Gallo Images via Getty Images


South Africa recently announced the start of the country’s first COVID-19 vaccine clinical trial. The vaccine is also being tested in the UK and Brazil. Ina Skosana spoke to the vice-president for research at the South African Medical Research Council, Professor Jeffrey Mphahlele, to find out more.

How big is the trial and who’s involved?

The trial is a joint effort between different stakeholders. The main player is the University of the Witwatersrand, under the leadership of Professor Shabir Madhi. The South African Medical Research Council is co-funding the project with R10 million. Other funders include the Bill and Melinda Gates Foundation and vaccine developers at the University of Oxford.

In South Africa the aim is to vaccinate around 2000 volunteers. This will happen in at least three different groups. Half of the participants will receive the experimental vaccine and half will receive placebo. They’ll be followed for about a year to assess the safety of and the immune response to the experimental vaccine.

Before enrolling the large group of volunteers, the trial will start with a group of about 50 HIV negative healthy volunteers to evaluate the vaccine safety and to a limited extend immune response. Later, the trial aims to investigate the vaccine safety and ability to mount the immune response in HIV positive volunteers. It’s important to test the vaccine in a participants with HIV given the high burden of HIV and AIDS in South Africa and the continent.

It’s prudent to evaluate the safety of the vaccine in this group during the clinical trial and not to wait until the vaccine is licensed. Even so, the vaccine, once licensed, will be for everybody.

At this stage, this particular vaccine candidate (ChAdOx1) is being tested in South Africa, Brazil and the UK.

If and when the vaccine is licensed, the aim is to make it a public good and available to all countries in the world – rich and poor.

What is the significance of Africa’s involvement?

It’s critical that developing countries are involved in clinical trials because it’s important to test the vaccine in different populations.

If the vaccine candidate is developed and tested in high income countries only, the efficacy may not necessarily be the same in populations living in low- and middle-income countries.

This has happened with vaccines before.

One example was the rotavirus vaccine candidates. The purpose of the rotavirus vaccine is to protect against dehydration and severe gastroenteritis. Early vaccine candidates demonstrated high efficacy of over 80% when tested in developed countries with low child mortality. But when the same vaccines were tested in low-income and middle-income countries of Africa and Asia, the efficacy was between 40% and 65%.

That did not rule out the use of rotavirus vaccines in the developing world. In fact, research has now shown that there has been a significant reduction in hospital or emergency unit admissions for acute rotavirus gastroenteritis, or mortality in children under five years old, in countries with rotavirus vaccination programmes. This was particularly true for low-income and middle-income countries with high child mortality.

There are a number of reasons why vaccine efficacy differs. These include the genetic background of the population. With the rotavirus vaccine, additional factors that are thought to affect optimal vaccine efficacy may include early age of first infection before administration of the first vaccine dose, maternal antibodies, distinct medical problems (high levels of HIV, TB, malaria, high background of enteric infections and malnutrition), and unique diversity of circulating rotavirus strains not included in the vaccines.

In the case of COVID-19 the virus seems to be genetically stable. This is a big plus.

What challenges does this trial present?

The most important challenge is the fact that a clinical trial is being conducted in the middle of a pandemic. It means that countries are having to deal with managing a public health emergency while simultaneously setting aside resources to do research.

Public health emergencies demand a response programme that is effective and nimble. No doubt the number one priority is to save lives and contain the epidemic. The recent Ebola outbreak in West Africa was a game changer in many ways. The outbreak spiralled out of control to become a global public health emergency due to a number of factors ranging from poor health systems to lack of medical innovations. When the cause of public health emergencies is known or predictable, and the tools to respond and intervene are widely available, it is always easy to respond and save lives.

We have learned a great deal since Ebola and other outbreaks. A key lesson is that research should take centre stage and become the norm in responding to a public health emergency – especially when the cause is unknown or novel – like with SARS-CoV-2. Rapid and responsive research during a public health emergency should aim to optimise and field test development of new health interventions such as vaccines, therapeutics and rapid diagnostic tools. It should also include socio-behavioural research, medical anthropology research and applied and translational research.

Read more:
Ebola in the DRC: the race is on between research and the virus

In the case of the COVID-19 vaccine trial in South Africa, rising numbers of infections create a conducive environment to conduct the trial because high levels of infections are needed to field test the vaccine efficacy. Doing this clinical trial at a time of low infections would take longer to yield such results. But now that the cases are spiking, we should be able to know sooner if the vaccine is likely to work or not.

As indicated above, this is not the first time research is conducted in the middle of an outbreak. We’ve got experience from Ebola, and other pathogens that were associated with outbreaks and epidemics like the original SARS, the MERS coronavirus and the Zika virus. These viruses were associated with epidemics – obviously not to the same magnitude as SARS-CoV-2.

Read more:
Mutating coronavirus: what it means for all of us

We just need to keep a balance between saving lives and doing research. In a pandemic like this one, the priority is to save lives. But there’s a limit in what we can use to save lives unless research innovation takes centre stage. Initially, the focus was on diagnostic tests. This has now shifted to treatment and the prevention regimens.

We’re making strides in treatment and prevention strategies. Recent breakthroughs include the use of remdesivir from the US and dexamethasone from UK for COVID-19 related treatment.

How is this trial similar to others?

Clinical trials are standardised so I don’t see this trial being different from others. Researchers should conduct trials following established legal, ethical and regulatory procedures governing conduct of trials. These include, but are not limited to, obtaining clearance from the South African Health Products Regulatory Authority and institutional Human Research Ethics Committees.The Conversation

Jeffrey Mphahlele, Vice President for Research, South African Medical Research Council

This article is republished from The Conversation under a Creative Commons license. Read the original article.

    Don’t miss out on the latest local news, interviews and competitions.

    Don’t miss out on the latest local news, interviews and competitions.

    Receive the latest news

    Subscribe To Our Newsletter



    Copyright Notice


    1.1 The contents of this Website, including but not limited to its compilation and arrangement, is the exclusive property of Kaya 959, alternatively the suppliers of content to Kaya 959, and accordingly remain protected by South African and International Copyright and Trademark laws.

    1.2 Any person accessing this Website, may not, save for downloading one copy for their personal computers and solely for their private and non-commercial use :

    1.2.1 Copy, disseminate, distribute, advertise, publish, adapt, modify or in any way reproduce the contents of this website for commercial purposes, unless this notice and any disclaimer attached thereto is published in its entirety, or unless the permission of Kaya 959 is obtained in writing.

    Privacy Policy


    POPIA ActTo promote the protection of personal information processed by public and private bodies; to introduce certain conditions so as to establish minimum requirements for the processing of personal information; to provide for the establishment of an Information Regulator to exercise certain powers and to perform certain duties and functions in terms of this Act and the Promotion of Access to Information Act, 2000; to provide for the issuing of codes of conduct; to provide for the rights of persons regarding unsolicited electronic communications and automated decision making; to regulate the flow of personal information across the borders of the Republic; and to provide for matters connected therewith.


    • section 14 of the Constitution of the Republic of South Africa, 1996, provides that everyone has the right to privacy;
    • the right to privacy includes a right to protection against the unlawful collection, retention, dissemination and use of personal information;
    • the State must respect, protect, promote and fulfil the rights in the Bill of Rights;


    • consonant with the constitutional values of democracy and openness, the need for economic and social progress, within the framework of the information society, requires the removal of unnecessary impediments to the free flow of information, including personal information;


    • regulate, in harmony with international standards, the processing of personal information by public and private bodies in a manner that gives effect to the right to privacy subject to justifiable limitations that are aimed at protecting other rights and important interests,
    1. Definitions and Interpretation

    1.1.“Personal Information” means information relating to an identifiable, living, natural person and where it is applicable, identifiable, existing juristic person, including all information as defined in the Protection of Personal Information Act 4 of 2013. 

    1.2  Parliament assented to POPIA on 19 November 2013. The commencement date of section 1Part A of Chapter 5section 112 and section 113 was 11 April 2014. The commencement date of the other sections was 1 July 2020 (with the exception of section 110 and 114(4). The President of South Africa has proclaimed the POPI commencement date to be 1 July 2020.

    1.3. “Processing” means the creation, generation, communication, storage, destruction of personal information as more fully defined in the Protection of Personal Information Act 4 of 2013.  

    1.4. “You” or the “user” means any person who accesses and browses this website for any purpose. 

    1.4. “Website” means the website of the KAYA 959 at URL www.kaya959.co.za or such other URL as KAYA 959 may choose from time to time.   

    1. Status and Amendments

    2.1. KAYA 959 respects your privacy. This privacy policy statement sets out KAYA 959’s information gathering and dissemination practices in respect of the Website. 

    2.2. This Privacy Policy governs the processing of personal information provided to KAYA 959 through your use of the Website. 

    2.3. Please note that, due to legal and other developments, KAYA 959 may amend these terms and conditions from time to time.  

    1. Processing of Personal Information

    3.1. By providing your personal information to KAYA 959 you acknowledge that it has been collected directly from you and consent to its processing by KAYA 959. 

    3.2. Where you submit Personal Information (such as name, address, telephone number and email address) via the website (e.g. through completing any online form) the following principles are observed in the processing of that information: 

    3.2.1. KAYA 959 will only collect personal information for a purpose consistent with the purpose for which it is required. The specific purpose for which information is 
    collected will be apparent from the context in which it is requested. 

    3.2.2. KAYA 959 will only process personal information in a manner that is adequate, relevant and not excessive in the context of the purpose for which it is processed. 

    3.2.3. Personal information will only be processed for a purpose compatible with that for which it was collected, unless you have agreed to an alternative purpose in writing or KAYA 959 is permitted in terms of national legislation of general application dealing primarily with the protection of personal information. 

    3.2.4. KAYA 959 will keep records of all personal Information collected and the specific purpose for which it was collected for a period of 1 (one) year from the date on which it was last used. 

    3.2.5. KAYA 959 will not disclose any personal information relating to you to any third party unless your prior written agreement is obtained or KAYA 959 is required to do so by law. 

    3.2.6. If personal information is released with your consent KAYA 959 will retain a record of the information released, the third party to which it was released, the reason for the release and the date of release, for a period of 1 (one) year from the date on which it was last used. 

    3.2.7. KAYA 959 will destroy or delete any personal information that is no longer needed by KAYA 959 for the purpose it was initially collected, or subsequently processed. 

    3.3. Note that, as permitted by the Electronic Communications and Transactions Act 25 of 2002, KAYA 959 may use personal information collected to compile profiles for statistical purposes. No information contained in the profiles or statistics will be able to be linked to any specific user.    

    1. Collection of anonymous data

    4.1. KAYA 959 may use standard technology to collect information about the use of this website. This technology is not able to identify individual users but simply allows KAYA 959 to collect statistics. 

    4.2. KAYA 959 may utilise temporary or session cookies to keep track of users’ browsing habits. A cookie is a small file that is placed on your hard drive in order to keep a record of your interaction with this website and facilitate user convenience. 

    4.2.1. Cookies by themselves will not be used to identify users personally but may be used to compile identified statistics relating to use of services offered or to provide KAYA 959 with feedback on the performance of this website. 

    4.2.2. The following classes of information may be collected in respect of users who have enabled cookies: The browser software used; IP address; Date and time of activities while visiting the website; URLs of internal pages visited; and referrers. 

    4.3. If you do not wish cookies to be employed to customize your interaction with this website it is possible to alter the manner in which your browser handles cookies. Please note that, if this is done, certain services on this website may not be available. 

    1. Security

    5.1. KAYA 959 takes reasonable measures to ensure the security and integrity of information submitted to or collected by this website, but cannot under any circumstances be held liable for any loss or other damage sustained by you as a result of unlawful access to or dissemination of any personal information by a third party. 

    1. Links to other websites

    6.1. KAYA 959 has no control over and accepts no responsibility for the privacy practices of any third party websites to which hyperlinks may have been provided and KAYA 959 strongly recommends that you review the privacy policy of any website you visit before using it further. 

    1. Queries

    7.1. If you have any queries about this privacy policy please contact us by emailing [email protected] 

    Competition Terms and Conditions

    • The competitions are open to all persons over the age of 18 years; except directors, partners, employees, agents, service providers, and consultants of Kaya 959, the sponsor and all its subsidiaries and its holding company, if any, as well as all spouses, life partners, parents, children, siblings, business partners and associates of such persons.

    • The outcome of the competition is subject to the decision of the judge/presenter, whose decision is final and no negotiation will be entered into thereafter. Neither Kaya 959, sponsors nor their agents will be held responsible or answerable to any dispute arising from the competition or prize awards.

    • Participants/listeners enter or take part in competitions at their own risk and Kaya 959 bears no responsibility for any loss, damage or harm suffered as a result of participation in any of Kaya 959 competition.

    • One listener is entitled to winning one prize in a period of 3 months. Kaya 959 reserves the right not to award a prize if the listener has won a prize prior during the 3 month window period. This also applies to listeners who provide family or friend’s contact details.

    • Kaya 959 reserves the right to redistribute all unclaimed prizes if not claimed after 3 months after being given away On Air or on the website.

    • Prizes are not transferable and may not be exchanged for cash.

    • Finalists will forfeit their participation in the competition if they fail to attend the draws.

    • The competition will run during the period advertised on Kaya 959; entries received outside of the competition period will not be considered for the competition draw.

    • Kaya 959 and their sponsors reserve the right to cancel, modify or amend the competition at any time if deemed necessary in their opinion, or if circumstances arise outside of their control.

    • By entering the competition, entrants agree to accept these rules and to be bound by them.